- Home
- WAT
as 11-15-2024 4:00pm EST
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
| Founded: | 1958 | Country: | United States |
| Employees: | N/A | City: | MILFORD |
| Market Cap: | 22.5B | IPO Year: | 1995 |
| Target Price: | $357.85 | AVG Volume (30 days): | 527.7K |
| Analyst Decision: | Hold | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 10.48 | EPS Growth: | -4.76 |
| 52 Week Low/High: | $258.90 - $393.38 | Next Earning Date: | 11-01-2024 |
| Revenue: | $2,905,147,000 | Revenue Growth: | -3.01% |
| Revenue Growth (this year): | 0.49% | Revenue Growth (next year): | 5.55% |
Latest Waters Corporation News
WAT Breaking Stock News: Dive into WAT Ticker-Specific Updates for Smart Investing
Morningstar Research
2 days ago
Analyst Report: Waters Corporation
Insider Monkey
2 days ago
What Contributed To The Performance Of Waters Corporation (WAT) In Q3?
Insider Monkey
3 days ago
Waters Corporation (WAT) Surged on Improved Demand
Zacks
3 days ago
Should You Invest in the First Trust Water ETF (FIW)?
PR Newswire
4 days ago
Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK
PR Newswire
10 days ago
Waters New Software Delivers Lab-Centric Business Intelligence and Enables Confident Audit-Readiness
Argus Research
12 days ago
WAT: Raising target price to $407.00
Zacks
13 days ago
Waters Stock Gains on Earnings & Sales Beat in Q3, Raised View
Compare WAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "WAT Waters Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.